Biocon Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020
October 22, 2020 at 02:50 pm EDT
Share
Biocon Limited announced earnings results for the second quarter ended September 30, 2020. For the second quarter, the company announced total revenue was INR 17,603 million compared to INR 16,057 million a year ago. Net income was INR 1,693 million compared to INR 2,157 million a year ago. Basic earnings per share was INR 1.43 compared to INR 1.82 a year ago. Diluted earnings per share was INR 1.41 compared to INR 1.82 a year ago. Basic earnings per share from continuing operations was INR 1.47 compared to INR 1.9 a year ago. Diluted earnings per share from continuing operations was INR 1.45 compared to INR 1.9 a year ago. For the half year, total revenue was INR 34,499 million compared to INR 30,887 million a year ago. Net income was INR 3,187 million compared to INR 4,220 million a year ago. Basic earnings per share was INR 2.69 compared to INR 3.57 a year ago. Diluted earnings per share was INR 2.66 compared to INR 3.56 a year ago. Basic earnings per share from continuing operations was INR 2.76 compared to INR 3.72 a year ago. Diluted earnings per share from continuing operations was INR 2.73 compared to INR 3.71 a year ago.
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
BIOCON LIMITED 
